CoChat

Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation

Open access

Published version of a preprint

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Drug repurposing represents an attractive alternative to the costly and time-consuming process of new drug development, particularly for serious, widespread conditions with limited effective treatments, such as Alzheimer’s disease (AD). Emerging generative artificial intelligence (GAI) technologies like ChatGPT offer the promise of expediting the review and summary of scientific knowledge. To examine the feasibility of using GAI for identifying drug repurposing candidates, we iteratively tasked ChatGPT with proposing the twenty most promising drugs for repurposing in AD, and tested the top ten for risk of incident AD in exposed and unexposed individuals over age 65 in two large clinical datasets: (1) Vanderbilt University Medical Center and (2) the All of Us Research Program. Among the candidates suggested by ChatGPT, metformin, simvastatin, and losartan were associated with lower AD risk in meta-analysis. These findings suggest GAI technologies can assimilate scientific insights from an extensive Internet-based search space, helping to prioritize drug repurposing candidates and facilitate the treatment of diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41746-024-01038-3

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 An illustration of the study design. a Employing iterative queries of ChatGPT to recommend twenty drugs for AD repurposing. b Evaluating the potential efficacy of the ten most frequently suggested drugs using electronic health records (EHR) data from two large clinical databases.
Fig. 1 An illustration of the study design. a Employing iterative queries of ChatGPT to recommend twenty drugs for AD repurposing. b Evaluating the potential efficacy of the ten most frequently suggested drugs using electronic health records (EHR) data from two large clinical databases.CC BY · PubMed Central
Fig. 2 Associations between exposure to ChatGPT-suggested drug repurposing candidates and AD risk. Hazard ratios (HR) and 95% confidence intervals (CI) are shown for VUMC (blue squares), the NIH All of Us Research Program (red squares), and the combined meta-analysis (gray squares). ** indicates drugs associated with significantly reduced AD risk using VUMC data (p < 0.05); * indicates drugs associated with significantly reduced AD risk in the meta-analysis (p < 0.05). To ensure adequate statistical power, we did not report drugs with fewer than five AD cases in the study cohort (i.e., bexarotene and nilotinib in both VUMC and All of Us; minocycline, candesartan, rapamycin, and lithium in All of Us).
Fig. 2 Associations between exposure to ChatGPT-suggested drug repurposing candidates and AD risk. Hazard ratios (HR) and 95% confidence intervals (CI) are shown for VUMC (blue squares), the NIH All of Us Research Program (red squares), and the combined meta-analysis (gray squares). ** indicates drugs associated with significantly reduced AD risk using VUMC data (p < 0.05); * indicates drugs associated with significantly reduced AD risk in the meta-analysis (p < 0.05). To ensure adequate statistical power, we did not report drugs with fewer than five AD cases in the study cohort (i.e., bexarotene and nilotinib in both VUMC and All of Us; minocycline, candesartan, rapamycin, and lithium in All of Us).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 82

Metadata

Authors
Yan, C., Grabowska, M. E., Dickson, A. L., Li, B., Wen, Z., Roden, D. M., Michael Stein, C., Embí, P. J., Peterson, J. F., Feng, Q., Malin, B. A., & Wei, W.-Q.
Affiliations
  • Vanderbilt University Medical Center (US)
  • Vanderbilt University (US)
  • Emory University (US)
Corresponding author
Wei, Wei-Qi
Venue
npj Digital Medicine
Published
2024-02-26
Volume
7
Issue
1
Pages
46-46
ISSN
2398-6352 (ISSN-L)
OpenAlex
W4392162026
Cited by
73
References
40
Citations by year
2026: 23 · 2025: 37 · 2024: 13
FWCI
20.78
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Digital Medicine (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG069900, F30AG080885)
  • U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM139891, R35GM131770)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
drug repurposing, Alzheimer's disease, generative AI, ChatGPT, candidate prioritization, metformin, simvastatin, losartan, older adults, real-world clinical data, All of Us

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation. https://app.cochat.ai/papers/10.1038/s41746-024-01038-3
The paper
Yan, C., Grabowska, M. E., Dickson, A. L., Li, B., Wen, Z., Roden, D. M., Michael Stein, C., Embí, P. J., Peterson, J. F., Feng, Q., Malin, B. A., & Wei, W.-Q. (2024). Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation. npj Digital Medicine. https://doi.org/10.1038/s41746-024-01038-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.